Toralgen Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.7M

  • Investors
  • 4

Toralgen General Information

Description

Operator of a preclinical stage biopharmaceutical company intended to focus on the development and commercialization of human therapeutics. The company offers a poly-bile nano-particle platform that eliminates the challenges of oral delivery to fabricate nano-pill and improve outcomes through optimized and targeted drug delivery, enabling healthcare providers to improve the lives of their patients.

Contact Information

Website
www.toralgen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1220 Waterway Boulevard
  • Suite H123
  • Indianapolis, IN 46202
  • United States
+1 (317)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Vertical(s)
Nanotechnology, HealthTech, Life Sciences
Corporate Office
  • 1220 Waterway Boulevard
  • Suite H123
  • Indianapolis, IN 46202
  • United States
+1 (317)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Toralgen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 01-Feb-2025 $4.7M Completed Pre-Clinical Trials
1. Seed Round 22-Oct-2020 Completed Pre-Clinical Trials
To view Toralgen’s complete valuation and funding history, request access »

Toralgen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed 2
Seed
To view Toralgen’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Toralgen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Toralgen Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Elevate Ventures Venture Capital Minority
Solyco Capital PE/Buyout Minority
Talon Group Venture Capital Minority
VisionTech Partners Angel Group Minority
To view Toralgen’s complete investors history, request access »

Ready to get started?

Request a free trial

Toralgen FAQs

  • When was Toralgen founded?

    Toralgen was founded in 2017.

  • Where is Toralgen headquartered?

    Toralgen is headquartered in Indianapolis, IN.

  • What is the size of Toralgen?

    Toralgen has 9 total employees.

  • What industry is Toralgen in?

    Toralgen’s primary industry is Pharmaceuticals.

  • Is Toralgen a private or public company?

    Toralgen is a Private company.

  • What is Toralgen’s current revenue?

    The current revenue for Toralgen is .

  • How much funding has Toralgen raised over time?

    Toralgen has raised $13M.

  • Who are Toralgen’s investors?

    Elevate Ventures, Solyco Capital, Talon Group, and VisionTech Partners have invested in Toralgen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »